D. Mason

Publications19
h-index13
Citations2,538
Highly Influential Citations100
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • P. Rutgeerts
  • 1,673 Publications • 109,468 Citations
  • S. Hanauer
  • 989 Publications • 74,736 Citations
  • W. Sandborn
  • 2,058 Publications • 115,441 Citations
  • S. Schreiber
  • 1,513 Publications • 129,582 Citations
  • Publications
  • Influence
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
TLDR
Certolizumab pegol plus MTX was more efficacious than placebo plusMTX, rapidly and significantly improving signs and symptoms of RA and physical function and inhibiting radiographic progression.
Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized,…
TLDR
Treatment with certolizumab pegol 200 or 400 mg plusMTX resulted in a rapid and sustained reduction in RA signs and symptoms, inhibited the progression of structural joint damage, and improved physical function as compared with placebo plus MTX treatment in RA patients with an incomplete response to MTX.
Certolizumab pegol for the treatment of Crohn's disease.
TLDR
In patients with moderate-to-severe Crohn's disease, induction and maintenance therapy with certolizumab pegol was associated with a modest improvement in response rates, as compared with placebo, but with no significant improvement in remission rates.
Quantitative assessment of sustained‐release 4‐aminopyridine for symptomatic treatment of multiple sclerosis
TLDR
The quantitative outcomes used in this study permit more sensitive evaluation of the therapeutic effect and promise to be useful in future trials of symptomatic treatments for MS.
Clinical and Mucosal Improvement With Specific Carbohydrate Diet in Pediatric Crohn Disease
TLDR
Clinical and mucosal improvements were seen in children with CD, who used SCD for 12 and 52 weeks and CE can monitor mucosal improvement in treatment trials for pediatric CD, and further studies are critically needed to understand the mechanisms underlying SCD's effectiveness.
Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR).
TLDR
This is the first head-to-head comparison of the multidose pharmacokinetics of these two new formulations of CBZ, and CBTL b.i.d. and TXR were bioequivalent in their pharmacokinetic parameters for CBZ and CBZ-E after 5 days of dosing.
Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans.
TLDR
It is demonstrated that inhibition of c-Myc expression by antisense phosphorodiamidate morpholino oligomer is a promising new and safe therapeutic strategy for prostate cancer.
Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury.
TLDR
The first evidence of therapeutic benefit of fampridine-SR in SCI patients is provided, and the clinical benefits most likely derive from the K+ channel blocking action of the drug.
Reanalysis of carbamazepine and carbamazepine-epoxide pharmacokinetics after multiple dosing of extended release formulation.
TLDR
The investigation of CBZ and CBZ-E pharmacokinetics from this study suggested that autoinduction might occur by the fifth day of dosing and might partly contribute to the sigmoidal shape of CBz-E profiles.
Active Specific Immunotherapy with a β-Human Chorionic Gonadotropin Peptide Vaccine in Patients with Metastatic Colorectal Cancer: Antibody Response Is Associated with Improved Survival
TLDR
Vaccination with CTP37-DT induced anti-hCG antibody induction was associated with longer overall survival and has an excellent safety profile and warrants further study in patients with colorectal cancer.
...
1
2
...